Home > Compound List > Product Information
Tenofovir_Molecular_structure_CAS_147127-20-6)
Click picture or here to close

Tenofovir

Catalog No. DB00300 Name DrugBank
CAS Number 147127-20-6 Website http://www.ualberta.ca/
M. F. C9H14N5O4P Telephone (780) 492-3111
M. W. 287.212321 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 185

SYNONYMS

IUPAC name
({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid
IUPAC Traditional name
tenofovir
Brand Name
Apropovir
Viread
Synonyms
PMPA
D,L-Tenofovir
Tenofovir disoproxil
TDF
Tenofovir disoproxil fumarate

DATABASE IDS

PubChem CID 464205
CAS Number 147127-20-6
PubChem SID 46508131

PROPERTIES

Hydrophobicity(logP) -1.6
Solubility 13.4 mg/mL in distilled water at 25oC (disoproxil fumarate salt)

DETAILS

Description (English)
Item Information
Drug Groups approved; investigational
Description Tenofovir, marketed by Gilead Sciences under the trade name Viread®, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. [Wikipedia]
Indication For use, in combination with other antiretroviral agents, for the treatment of HIV-1 infection.
Pharmacology Tenofovir belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NtRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. Tenofovir is currently in late-stage clinical trials for the treatment of hepatitis B. Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Tenofovir requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.
Toxicity Limited clinical experience at doses higher than the therapeutic dose of tenofovir 300 mg is available. In Study 901 tenofovir disoproxil fumarate 600 mg was administered to 8 patients orally for 28 days. No severe adverse reactions were reported. The effects of higher doses are not known.
Affected Organisms
Human Immunodeficiency Virus
Biotransformation Neither tenofovir disoproxil nor tenofovir are substrates of CYP450 enzymes.
Absorption The oral bioavailability in fasted patients is approximately 25%. Administration of food (high fat meal containing 40 to 50% fat) increases the oral bioavailability, with an increase in the AUC of approximately 40%.
Half Life Approximately 17 hours.
Protein Binding Very low: < 0.7% to human plasma proteins and < 7.2% to serum proteins
Distribution * 1.3 ± 0.6 L/kg [tenofovir 1.0 mg/kg]
* 1.2 ± 0.4 L/kg [tenofovir 3.0 mg/kg]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

REFERENCES